Spots Global Cancer Trial Database for Zevalin-beam for Aggressive Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Zevalin-beam for Aggressive Lymphoma
Official Title: SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Study ID: NCT00491491
Conditions
Study Description
Brief Summary: The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall and disease-free survival.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic Arizona, Scottsdale, Arizona, United States
City of Hope National Medical Center, Duarte, California, United States
Cedars Sinai Medical Center, Los Angeles, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Northwestern University, Chicago, Illinois, United States
Mayo Clinic, Rochester, Minnesota, United States
Georg-August Universität, Göttingen, , Germany
Chaim Sheba Medical Center, Tel Hashomer, , Israel
VU Medical Center, Amsterdam, , Netherlands
Contact Details
Name: Avichai Shimoni, MD
Affiliation: Chaim Sheba Medical Center, Tel Hashomer, Israel
Role: STUDY_CHAIR
Name: Amrita Krishnan, MD
Affiliation: City of Hope National Medical Center, Duarte, CA
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
